Cargando…
Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices
OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist de...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272823/ https://www.ncbi.nlm.nih.gov/pubmed/37332585 http://dx.doi.org/10.3389/fcvm.2023.1158248 |
_version_ | 1785059583442550784 |
---|---|
author | Pausch, Jonas Mersmann, Julian Bhadra, Oliver D. Barten, Markus J. Tönnis, Tobias Yildirim, Yalin Pecha, Simon Reichenspurner, Hermann Bernhardt, Alexander M. |
author_facet | Pausch, Jonas Mersmann, Julian Bhadra, Oliver D. Barten, Markus J. Tönnis, Tobias Yildirim, Yalin Pecha, Simon Reichenspurner, Hermann Bernhardt, Alexander M. |
author_sort | Pausch, Jonas |
collection | PubMed |
description | OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist device (LVAD) recipients remains controversial. METHODS: 162 consecutive HF patients, who underwent LVAD implantation at our institution between 2010 and 2019, were categorized according to the presence (n = 94, ICD-group) or absence (n = 68, Control-group) of ICDs. Apart from clinical baseline and follow-up parameters, adverse events (AEs) related to ICD therapy and overall survival rates were retrospectively analyzed. RESULTS: Out of 162 consecutive LVAD recipients 79 patients (48.8%) were preoperatively categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile ≤2. The prevalence of severe HF symptoms and preoperative use of short-term circulatory support devices (54.4% vs. 13.8%, p < 0.001) was higher within the Control-group, although baseline severity of LV and RV dysfunction was similar. Apart from an increased prevalence of perioperative right heart failure (RHF) within the Control-group (45.6% vs. 17.0%; p < 0.001), procedural characteristics and perioperative outcome were similar. Overall-survival during a median follow-up of 14 (3.0–36.5) months was similar within both groups (p = 0.46). During the first 2 years after LVAD implantation 53 ICD-related AEs occurred within the ICD-group. Thereof, lead-dysfunction occurred in 19 patients and unplanned ICD-reintervention in 11 patients. Furthermore, in 18 patients appropriate shocks without loss of consciousness occurred, whereas inappropriate shocks occurred in 5 patients. CONCLUSION: ICD therapy in LVAD recipients was not associated with a survival benefit or reduced morbidity after LVAD implantation. Conservative ICD-programming seems to be justified to avoid ICD-related complications and „awake shocks” after LVAD implantation. |
format | Online Article Text |
id | pubmed-10272823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102728232023-06-17 Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices Pausch, Jonas Mersmann, Julian Bhadra, Oliver D. Barten, Markus J. Tönnis, Tobias Yildirim, Yalin Pecha, Simon Reichenspurner, Hermann Bernhardt, Alexander M. Front Cardiovasc Med Cardiovascular Medicine OBJECTIVES: Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist device (LVAD) recipients remains controversial. METHODS: 162 consecutive HF patients, who underwent LVAD implantation at our institution between 2010 and 2019, were categorized according to the presence (n = 94, ICD-group) or absence (n = 68, Control-group) of ICDs. Apart from clinical baseline and follow-up parameters, adverse events (AEs) related to ICD therapy and overall survival rates were retrospectively analyzed. RESULTS: Out of 162 consecutive LVAD recipients 79 patients (48.8%) were preoperatively categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile ≤2. The prevalence of severe HF symptoms and preoperative use of short-term circulatory support devices (54.4% vs. 13.8%, p < 0.001) was higher within the Control-group, although baseline severity of LV and RV dysfunction was similar. Apart from an increased prevalence of perioperative right heart failure (RHF) within the Control-group (45.6% vs. 17.0%; p < 0.001), procedural characteristics and perioperative outcome were similar. Overall-survival during a median follow-up of 14 (3.0–36.5) months was similar within both groups (p = 0.46). During the first 2 years after LVAD implantation 53 ICD-related AEs occurred within the ICD-group. Thereof, lead-dysfunction occurred in 19 patients and unplanned ICD-reintervention in 11 patients. Furthermore, in 18 patients appropriate shocks without loss of consciousness occurred, whereas inappropriate shocks occurred in 5 patients. CONCLUSION: ICD therapy in LVAD recipients was not associated with a survival benefit or reduced morbidity after LVAD implantation. Conservative ICD-programming seems to be justified to avoid ICD-related complications and „awake shocks” after LVAD implantation. Frontiers Media S.A. 2023-06-02 /pmc/articles/PMC10272823/ /pubmed/37332585 http://dx.doi.org/10.3389/fcvm.2023.1158248 Text en © 2023 Pausch, Mersmann, Bhadra, Barten, Tönnis, Yildirim, Pecha, Reichenspurner and Bernhardt. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Pausch, Jonas Mersmann, Julian Bhadra, Oliver D. Barten, Markus J. Tönnis, Tobias Yildirim, Yalin Pecha, Simon Reichenspurner, Hermann Bernhardt, Alexander M. Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title | Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title_full | Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title_fullStr | Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title_full_unstemmed | Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title_short | Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
title_sort | prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272823/ https://www.ncbi.nlm.nih.gov/pubmed/37332585 http://dx.doi.org/10.3389/fcvm.2023.1158248 |
work_keys_str_mv | AT pauschjonas prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT mersmannjulian prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT bhadraoliverd prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT bartenmarkusj prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT tonnistobias prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT yildirimyalin prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT pechasimon prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT reichenspurnerhermann prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices AT bernhardtalexanderm prognosticimpactofimplantablecardioverterdefibrillatorsandassociatedadverseeventsinpatientswithcontinuousflowleftventricularassistdevices |